Search Videos and More
News
Exploring the Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy: A Prospective Study
This phase II trial tests the effect of hemp-based cannabidiol (CBD) in preventing oxaliplatin (Ox)-induced peripheral neuropathy (OIPN) in patients with colorectal cancer (CRC) that has spread to nearby tissue or lymph nodes and cannot be removed by surgery (locally advanced unresectable) or that has spread from where it first started (primary site) to other places in the body (metastatic).
News
Pembrolizumab Maintenance After Enfortumab Vedotin/Pembrolizumab Induction in Frontline Metastatic Urothelial Carcinoma (IMPROEV)
This is a single-arm, open-label, non-randomized Phase II trial evaluating the efficacy of induction therapy with enfortumab vedotin (EV) plus pembrolizumab (P) for 18 weeks (6 cycles), followed by maintenance pembrolizumab in treatment-naïve patients with metastatic urothelial carcinoma (mUC).
News
Scrambler Therapy with Duloxetine-Based Usual Care vs. Duloxetine-Based Usual Care for Chemotherapy-Induced Peripheral Neuropathy
The investigators hypothesize that Scrambler therapy with duloxetine, compared to duloxetine-based usual care, will result in greater improvement in CIPN as measured by the BPI-Short Form.
News
Fox Chase Cancer Center Celebrates Innovation, Sustained Growth, and Upward Momentum
When it comes to cancer, our work can seem insurmountable. But look closer, and it offers enduring hope. Despite the demands — or perhaps because of them — the faculty and staff at Fox Chase Cancer Center steadily rise above to achieve more.
News
The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer
Diagnosing lymphoma and sarcoma can be extraordinarily complex, with more than 70 recognized subtypes of lymphoma and more than 100 distinct types of sarcoma. Many subtypes share similar features yet behave in dramatically different ways in standard testing, leaving oncologists with diagnostic quandaries and delays to treatment.
News
Delivering Big Ideas from ASH 2025
At Fox Chase Cancer Center and Temple University Hospital, it’s “in the blood” of our residents and Fellows to develop innovative scientific ideas that significantly affect the way blood diseases are diagnosed and treated. Here is the latest from ASH 2025:
News
Fellowship Training That Goes Where You Go
As Chief Fellow Giuliana Berardi, MD, a third-year Hematology/Oncology Fellow at Fox Chase Cancer Center, reflected on her medical training, she noted the steep learning curve that accompanied each new level of medical training.
News
Preparing for the Routine and Unforeseen in the Urologic OR
From 11 am to 11 pm, Joon Park, MSHI, BSN, RN, CNOR, Fox Chase Cancer Center Perioperative Evening Charge Nurse, manages the surgical staff workflow and patient assignments for the Fox Chase Cancer operating room.
News
Fox Chase Fellows Shape the World of Cancer Care
Wherever they go, Fox Chase Fellows and residents bring a significant contribution to the world of cancer care, from distinguished JAMA peer reviews to notable advances in the field of neuroendocrine cancer to accolades for research, academy leadership, and compassionate clinical care.
News
Unconventional and Exceptional: Dr. Lee’s Fox Chase Residency
Peter L. Lee, MD, PhD, has two distinct and interesting roles in radiation oncology at the Mass General Brigham Cancer Institute: one as radiation oncologist specializing in GU cancers, and another as a leader tasked to develop the hospital’s Exercise Oncology Program –a rapidly growing specialty that focuses on the benefits of exercise for cancer management.
News
Defeating Cancer Means Never Resting on Our Laurels
At Fox Chase Cancer Center, our faculty, fellows, and residents always look to the future to develop and collaborate on therapeutic breakthroughs to enhance life and extend it—never resting on accolades earned in the past.
News
Temple Health Appoints Alex Khariton, MBA, as Chief Operating Officer of Fox Chase Cancer Center
Fox Chase Cancer Center (Fox Chase) and Temple Health today announced that Alex Khariton, MBA, has been appointed Chief Operating Officer of Fox Chase and Senior Vice President for Cancer Services across Temple Health effective February 23, 2026.